Shots: Promedior to receive $390M up front and up to $1B development, regulatory and commercial milestones, making the total deal value as $1.39B. Roche to get full rights for Promedior’s […]readmore
Tags : Acquire
Shots: Stryker to acquire Wright Medical in all cash transaction for $30.75/share or a total equity value of $4.0B, making a total deal value as $5.4B. The acquisition is expected […]readmore
Shots: Alvotech to receive ~$45M as up front, equity investment, milestone while Yas Holding has acquired a 2.5% stake in Alvotech business and get rights to commercialize Alvotech’s three biosimilar […]readmore
Shots: Google to acquire Fitbit in all-cash transaction for $7.35/share, making the total deal value $2.1B. The transaction is expected to be closed in 2020 The acquisition will provide Google […]readmore
Shots: Zentiva acquires Alvogen’s CEE market consisting of 200+ generics and OTC therapies across multiple therapeutics areas which include brands like Lactacyd, Persen, EuBiotic. The transaction is expected to be […]readmore
Shots: The life science portfolio to be acquired includes label-free biomolecular characterization (FortéBio), chromatography hardware and resins, and microcarriers (SoloHill) businesses. The proposed transaction follows Danaher’s GE Biopharma business and […]readmore
Shots: Alexion acquires Achillion with initial all-cash transaction for ~$930M at $6.30/share, including Achillion’s cash on hand of ~$230M, CVRs as clinical & regulatory milestones if achieved within specified periods […]readmore
Shots: Cerecor to receive up front as $4.5M in cash & $12.5M in Aytu preferred stock, which is approx. 1.4x LTM revenue, plus the assumption of debt The transaction will […]readmore
Shots: UCB acquires Ra Pharma in all stock and cash transaction making total deal value $2.1B. Ra Pharma to receive $48 in cash for each share, representing a premium of […]readmore
Shots: Sobi acquires Dova Pharmaceutical in cash & stock transaction making a total deal value as $915M. Dova to receive upfront of $27.50/share in cash, $1.50/share on approval of Doptelet […]readmore